FDA approves Cabometyx for liver cancer

Exelixis Inc. (NASDAQ:EXEL) said Monday FDA approved Cabometyx cabozantinib to treat hepatocellular carcinoma patients previously treated with Nexavar sorafenib.

The approval comes two months after Exelixis’ partner Ipsen Group (Euronext:IPN; Pink:IPSEY) received approval from the EC for Cabometyx in the indication.